Nectar Lifesciences Operational Benchmarking
₹10.33-2.46%close, 9 Oct 2026
- Market cap
- ₹201 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹7.44 – ₹13.95
Nectar Lifesciences compared with sector peers on revenue, market capitalization, valuation, and return metrics.
Nectar Lifesciences sector benchmarking & peer comparison
Operational and financial KPI comparison against sector peers.
| Company | LTP (₹) | P/E | Market Cap (₹ cr) | Div Yield | Qtr Sales (₹ cr) | ROCE % |
|---|---|---|---|---|---|---|
| Nectar Lifesciences Limited | ₹10.33 | 22.5 | 201 | 1.2% | 50.17 | 14.5% |
| Median (1 Cos) | ₹10.33 | 22.5 | 201 | 1.2% | 50.17 | 14.5% |
Source: NSE sector index filings and financial statements. Data as of 9 October 2026. How this data is compiled.
Same Data For Peers
- Neuland Laboratories Limited operational benchmarking
- Natco Pharma Limited operational benchmarking
- Narayana Hrudayalaya Limited. operational benchmarking
- Morepen Laboratories Limited operational benchmarking
- Onesource Specialty Pharma Limited operational benchmarking
- Metropolis Healthcare Limited operational benchmarking
Trade Nectar Lifesciences With ATS
Track NECLIFE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.